The Viatris Pacira acquisition would transfer the non-opioid pain medicine company to Viatris in a $1.65 billion cash transaction. The companies signed the merger agreement on October 8 and expect the deal to close by the end of 2026, subject to tender and regulatory conditions.

Key Insights

  • The Viatris Pacira acquisition offers Pacira shareholders $36.50 in cash for each outstanding share.
  • The companies valued Pacira’s equity at $1.65 billion and expect the transaction to close by year-end.
  • Completion requires a majority of Pacira shares to be tendered and the applicable U.S. antitrust waiting period to expire.

Viatris Pacira Acquisition Sets $36.50 Cash Offer

Viatris agreed to launch a tender offer for all outstanding Pacira BioSciences shares at $36.50 per share in cash. The October 8 Form 8-K said the purchaser must begin the offer within 15 business days of signing the merger agreement.

The offer requires valid tenders representing more than 50% of Pacira’s outstanding shares when combined with shares already owned by the buyer and its affiliates. It also remains subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Act.

After the tender offer closes, the buyer plans a second-step merger under Delaware law without a separate shareholder vote. Remaining eligible shares would convert into the same $36.50 cash consideration, while properly perfected appraisal rights would remain governed by Delaware law.

Pacira Portfolio Adds Non-Opioid Pain Medicines

Pacira’s marketed portfolio includes EXPAREL for postsurgical pain management and ZILRETTA for osteoarthritis knee pain. The companies said Pacira generated about $746 million in revenue and $177 million in adjusted EBITDA during the 12 months ended June 30, 2026.

The joint transaction announcement said Viatris plans to use its commercial and international infrastructure to expand selected products. Those plans remain forward-looking, and investors should separate stated strategic goals from completed integration results.

Viatris expects to fund the purchase mainly with excess cash and use short-term borrowing for the remainder. Management said it expects minimal impact on its gross leverage ratio, but financing terms, transaction costs and final integration spending will determine the actual balance-sheet effect.

What Pacira Shareholders Should Watch

Pacira’s board unanimously approved the agreement and recommended that shareholders tender their shares. The agreement also includes a $62 million termination fee under specified circumstances, including a qualifying superior proposal accepted under the contract’s procedures.

The tender materials and Pacira’s Schedule 14D-9 will provide the operative offer terms once filed. Investors can use Fusion Market News guides on reading earnings reports, market capitalization and stock dilution to evaluate the transaction alongside Pacira’s financial position.

The agreement specifies how outstanding employee awards would be treated at closing. In-the-money options would generally convert to cash based on the difference between the $36.50 offer and the exercise price, while eligible restricted and performance awards would also convert under the merger terms.

The companies expect the transaction to add Pacira’s commercial, medical-affairs and research capabilities to Viatris. Pacira is also developing PCRX-201, a locally administered gene therapy in Phase 2 development for osteoarthritis of the knee, but clinical progress remains subject to the usual development and regulatory risks.

Viatris is scheduled to discuss the transaction alongside its third-quarter results on November 5. That update may provide more detail on financing, expected synergies and the timetable, although the tender filings will remain the primary legal documents for shareholders.

The deal is an announced transaction rather than a completed acquisition, and the offer had not started when the companies issued their release. Regulatory clearance, sufficient tenders and the other closing conditions remain the central risks before Pacira can become a wholly owned Viatris subsidiary and leave Nasdaq.

Featured image: Mina Rad via Unsplash.

Sharron Kendi is a seasoned crypto market analyst and writer with over three years of experience decoding blockchain trends, price movements, and market dynamics. She holds a Bachelor’s Degree in Commerce (Finance) from Kenyatta University, blending a solid academic foundation with a sharp eye for technical analysis and a deep understanding of on-chain data. Her work delivers clear, data-driven insights that empower investors to navigate the fast-evolving digital asset space with confidence.